Daclizumab induction therapy in liver transplant recipients with renal insufficiency ALIMENTARY PHARMACOLOGY & THERAPEUTICS Asrani, S. K., Kim, W. R., Pedersen, R. A., Charlton, M. R., Kremers, W. K., Therneau, T. M., Rosen, C. B., Dean, P. G. 2010; 32 (6): 776-786


The role of interleukin 2 (IL-2) receptor antibodies to avoid the nephrotoxic effects of calcineurin inhibitors in the early post-liver transplant (LT) period is not well defined.To examine the use of daclizumab induction in LT recipients with renal insufficiency.Between 2002 and 2005, 62 patients (median pre-LT creatinine 2.4 mg/dL, IQR 1.9-3.7) received daclizumab induction with tacrolimus being administered when serum creatinine was <2.0 mg/dL. A concurrent comparison group (n = 221, 2002-2005) received tacrolimus-based immunosuppression without daclizumab (median pre-LT creatinine 1.1 mg/dL, IQR 0.9-1.4). A second historical comparison group (n = 103, 1995-2005) not receiving daclizumab was matched to the daclizumab patients by pre-LT serum creatinine (2.2 mg/dL, IQR 1.8-3.1). All patients received mycophenolate mofetil and steroids.Serum creatinine improved in the daclizumab group (-1.0 mg/dL, IQR -2.2 to -0.4) and worsened in the concurrent comparison group (+0.2 mg/dL, IQR 0-0.5) from pre-LT to 4 months. However, there was no difference when daclizumab group was compared with the historical comparison group matched on pre-LT creatinine (median change: -0.8 mg/dL vs. -0.7 mg/dL). Daclizumab induction was not associated with improvement in renal function at 4 months (P = 0.34) after adjusting for pre-LT creatinine, age, gender, hepatitis C status and simultaneous liver kidney transplantation.The incremental benefit offered by induction therapy with IL-2 receptor antibodies to preserve renal function is questionable.

View details for DOI 10.1111/j.1365-2036.2010.04408.x

View details for Web of Science ID 000280972200008

View details for PubMedID 20659283

View details for PubMedCentralID PMC3606263